Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 53.54 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 2.49M shares and market capitalization of 4.94B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.

The one-year performance of Cytokinetics Incorporated stock is 67.89%, while year-to-date (YTD) performance is 17.46%. CYTK stock has a five-year performance of 331.77%. Its 52-week range is between 29.1 and 54.74, which gives CYTK stock a 52-week price range ratio of 91.26%

Cytokinetics Incorporated currently has a PE ratio of -12.70, a price-to-book (PB) ratio of 29.84, a price-to-sale (PS) ratio of 53.08, a price to cashflow ratio of 409.20, a PEG ratio of 2.32, a ROA of -36.78%, a ROC of -61.60% and a ROE of -285.76%. The company’s profit margin is -%, its EBITDA margin is -342.50%, and its revenue ttm is $62.19 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Cytokinetics Incorporated, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.04 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.15), with a target price of $64.55, which is +22.95% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 9.63, ATR14 : 3.06, CCI20 : 250.95, Chaikin Money Flow : 0.13, MACD : 1.64, Money Flow Index : 81.65, ROC : 35.54, RSI : 68.84, STOCH (14,3) : 92.71, STOCH RSI : 1.00, UO : 68.40, Williams %R : -7.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $451 052), B. Lynne Parshall (Sold 41 328 shares of value $1 609 047 ), Ching W. Jaw (Option Excercise at a value of $484 000), Ching W. Jaw (Sold 75 687 shares of value $2 865 185 ), David W. Cragg (Option Excercise at a value of $584 250), David W. Cragg (Sold 93 269 shares of value $3 532 061 ), Edward M. Kaye (Option Excercise at a value of $114 150), Edward M. Kaye (Sold 15 000 shares of value $675 000 ), Fady Ibraham Malik (Option Excercise at a value of $1 033 670), Fady Ibraham Malik (Sold 144 153 shares of value $5 680 287 ), John T. Henderson (Option Excercise at a value of $72 744), John T. Henderson (Sold 8 503 shares of value $340 120 ), Leonard Patrick Gage (Option Excercise at a value of $112 400), Leonard Patrick Gage (Sold 26 468 shares of value $1 094 023 ), Mark A. Schlossberg (Option Excercise at a value of $789 089), Mark A. Schlossberg (Sold 45 175 shares of value $1 569 694 ), Robert I. Blum (Option Excercise at a value of $1 243 878), Robert I. Blum (Sold 164 143 shares of value $6 273 276 ), Sandford Drexel Smith (Option Excercise at a value of $979 397), Sandford Drexel Smith (Sold 57 322 shares of value $2 491 674 ), Santo J. Costa (Option Excercise at a value of $106 800), Santo J. Costa (Sold 10 000 shares of value $373 477 ), Wendell D. Wierenga (Option Excercise at a value of $22 746), Wendell D. Wierenga (Sold 4 166 shares of value $184 854 )